Search the Newsreel

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook

IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough

Nasdaq, S&P 500 Futures Rise Ahead Of Nvidia Earnings, Fed Minutes: Why TSLA, SLS, IBRX, CAVA, POET, BA Are In Focus

Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …

Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing

Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …

Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss

Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages

Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …

Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …

Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.

Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data

Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …

IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11%

Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus

This article highlights several technology and growth companies, including Archer Aviation (ACHR), ImmunityBio (IBRX), Sphere 3D Corp. (ANY), Graphene Manufacturing Group (GMG), and Socket Mobile (SCKT), which are attracting investor attention due to recent corporate, technology, and strategic developments. Archer Aviation is expanding its …

ImmunityBio appoints Jim Yong Kim as vice chairman

ImmunityBio, Inc. (NASDAQ:IBRX) has announced the appointment of Dr. Jim Yong Kim as vice chairman, who will focus on international partnerships and global access initiatives within the newly created Office of the Executive Chairman. Dr. Kim, a former president of the World Bank Group …

ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach

ImmunityBio (IBRX) is under investor scrutiny after receiving marketing authorization in the UAE for ANKTIVA, used for bladder cancer and lung cancer. While the stock has seen significant year-to-date gains, its current valuation reflects rich revenue multiples and ongoing losses. Analysts present mixed views, …

Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold"

Wall Street Zen has upgraded Inhibrx Biosciences (NASDAQ:INBX) from a "Sell" to a "Hold" rating, bringing the consensus rating for the stock to "Hold" with an average price target of $150. This upgrade comes despite the company reporting a quarterly loss of $2.15 per …

Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next

ImmunityBio (IBRX) saw its stock rise by 6.6% following its Q2 2026 results and the expanded UAE marketing authorization for its immunotherapy ANKTIVA, now covering bladder and lung cancer in 34 countries. Despite increased revenue, the company reported wider net losses, highlighting the challenge …

ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value

ImmunityBio (IBRX) has shown strong stock performance with a 321.9% gain over three years, driven by recent approvals for ANKTIVA. However, the stock appears overvalued based on its current Price-to-Sales (P/S) ratio of 46.8x, significantly higher than the biotech industry average. While there is …

ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise …

The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, while reporting second-quarter 2026 revenue of US$51.24 million and a net loss of US$230.38 million. The …

ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake

ImmunityBio, Inc. (IBRX) is majority-controlled by Patrick Soon-Shiong and affiliated entities, who beneficially own 64.8% of the common stock, totaling 745,518,285 shares. This ownership is distributed among several entities, including Cambridge Equities, Nant Capital, California Capital Equity, and NantWorks. The report is based on …

Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday

Inhibrx Biosciences (INBX) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $2.28 per share, following a previous quarter where the company missed expectations with a $2.15 per share loss. The stock, which …

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period's loss of 10 cents. Total revenues …

(INBX) Volatility Zones as Tactical Triggers

This article analyzes Inhibrx Biosciences Inc Com (NASDAQ: INBX), highlighting positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It identifies elevated downside risk and provides AI-generated institutional trading strategies for different risk profiles. The analysis includes position trading, momentum …

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) reported a Q2 loss of $0.08 per share, surpassing the Zacks Consensus Estimate of a $0.09 loss and showing an 11.11% earnings surprise. The company also beat revenue estimates, posting $51.24 million against an estimated $48.45 million. ImmunityBio's stock has seen a …

Immunitybio Inc earnings missed by $0.14, revenue topped estimates

Immunitybio Inc (NASDAQ: IBRX) reported second-quarter EPS of $-0.22, missing analyst estimates by $0.14. However, the company's revenue of $51.24M surpassed the consensus estimate of $47.22M. The stock has seen a significant increase of 196.68% over the last 12 months, despite a recent 7.86% …

ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings

IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales

ImmunityBio (IBRX) reported record second-quarter revenue of $51.2 million, surpassing Wall Street estimates, largely driven by strong sales of its cancer therapy, Anktiva. Despite a wider net loss due to non-cash accounting charges, Chairman Patrick Soon-Shiong highlighted the company's focus on expanding Anktiva's applications …

ImmunityBio Releases Q2 2026 Financial Results

ImmunityBio, Inc. (IBRX) reported a net loss of $230.4M and a loss per share of $0.22 for Q2 2026, widening from Q2 2025 as the company invests in its immunotherapy platform. Despite increased losses, revenue grew significantly to $51.2M, up 92.0% year-over-year, driven by …

ImmunityBio, Inc. (IBRX) Q2 2026 Earnings

ImmunityBio, Inc. (IBRX) reported its Q2 2026 earnings, with an EPS of -$0.22 against an estimated -$0.08, and revenue of $51M, exceeding the $50M estimate. The company's ANKTIVA revenue saw a 94% year-over-year increase, marking its eighth consecutive quarter of sequential gains. The EPS …

Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M

ImmunityBio, Inc. (IBRX) reported Q2 revenue of $51.2 million, surpassing the FactSet estimate of $49.7 million. This earnings flash indicates stronger-than-expected revenue performance for the biotechnology company in the second quarter.

ImmunityBio Q2 revenue rises 92% to record $50.7 million

ImmunityBio (IBRX) reported a significant increase in Q2 2026 total revenue, reaching $51.2 million, with net product revenue up 92% year-over-year to a record $50.7 million. The company's ANKTIVA product continues to drive growth, marking its eighth consecutive quarter of sequential revenue increase, and …